OMX Nordic 40
|
2 358,72
|
-16,88
|
-0,71 %
|
Analysen zu OMX Nordic 40-Werten
| 02.09.25 | ABB Sector Perform | RBC Capital Markets | |
| 01.09.25 | Novo Nordisk Neutral | UBS AG | |
| 01.09.25 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 01.09.25 | AstraZeneca Hold | Deutsche Bank AG | |
| 01.09.25 | Hennes & Mauritz AB Sector Perform | RBC Capital Markets | |
| 01.09.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 29.08.25 | Novo Nordisk Neutral | UBS AG | |
| 29.08.25 | ABB Neutral | JP Morgan Chase & Co. | |
| 27.08.25 | Volvo AB Buy | Jefferies & Company Inc. | |
| 27.08.25 | AstraZeneca Hold | Deutsche Bank AG | |
| 27.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 26.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 26.08.25 | A.P. Moeller - Maersk A-S Underweight | JP Morgan Chase & Co. | |
| 25.08.25 | Volvo AB Buy | Jefferies & Company Inc. | |
| 21.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 20.08.25 | Volvo AB Buy | UBS AG | |
| 19.08.25 | ABB Sector Perform | RBC Capital Markets | |
| 19.08.25 | Volvo AB Outperform | RBC Capital Markets | |
| 19.08.25 | Hennes & Mauritz AB Equal Weight | Barclays Capital | |
| 19.08.25 | Novo Nordisk Neutral | UBS AG | |
| 18.08.25 | Novo Nordisk Neutral | UBS AG | |
| 18.08.25 | Hennes & Mauritz AB Underweight | JP Morgan Chase & Co. | |
| 14.08.25 | Volvo AB Overweight | JP Morgan Chase & Co. | |
| 12.08.25 | Novo Nordisk Neutral | UBS AG | |
| 11.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 08.08.25 | Hennes & Mauritz AB Hold | Jefferies & Company Inc. | |
| 08.08.25 | Novo Nordisk Neutral | UBS AG | |
| 08.08.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 08.08.25 | Novo Nordisk Halten | DZ BANK | |
| 07.08.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 07.08.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 07.08.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 06.08.25 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.08.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.08.25 | Novo Nordisk Neutral | UBS AG | |
| 05.08.25 | AstraZeneca Buy | UBS AG | |
| 05.08.25 | Novo Nordisk Neutral | UBS AG | |
| 04.08.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 04.08.25 | AstraZeneca Outperform | Bernstein Research | |
| 01.08.25 | Novo Nordisk Market-Perform | Bernstein Research |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.